Correction, November 4, 2026: An earlier version said that for shareholders the warrant liability meant dilution, not a cash outflow. That holds for ordinary exercise. The warrant forms the company filed also provide that, in a merger, tender offer or similar transaction, the part of a warrant that a holder’s ownership cap would block from exercising is bought out for cash at Black-Scholes value, paid by the company or its successor. The article now says so.
Correction, November 4, 2026: The title and social headline said selling and administrative spending now exceeds research. That was true for the third quarter ($33.0 million versus $23.5 million), not for the nine months ($72.6 million versus $79.1 million). Both now say third quarter.
Compass Pathways ended September with $444.0 million in cash, up from $149.6 million at the start of the year. Of the $433.1 million its financing activities brought in over nine months, 57% came from warrants sold in 2023 and 2025.
The quarterly report, filed November 3, shows a third-quarter net loss of $9.8 million, down from $137.7 million a year earlier, while operating expenses rose 39% to $56.4 million. The gap is accounting: a fall in the share price cut the value of prepaid warrants, which the company books as a $40.8 million gain, and a year earlier warrant fair-value changes produced a $101.3 million loss. Operating expenses and cash used in operations are the better guide to what Compass is spending.
The filing also shows how Compass built its cash and how fast commercial-readiness spending is growing. Selling and administrative costs exceeded research costs in the third quarter for the first time since at least early 2025, ahead of a launch the company expects in the first half of 2027 if the FDA approves COMP360, its synthetic psilocybin for treatment-resistant depression. The company estimates that its cash will fund operating expenses and capital expenditure into 2028. The filing gives no figure for what the launch will cost.
How Compass went from $150 million to $444 million
Counting restricted cash, Compass held $150.0 million on January 1 and $444.4 million on September 30; the $444.0 million the company cites is the unrestricted part. The cash-flow statement accounts for the change: $433.1 million from financing, $139.0 million used in operations, and no investing activity.
| Source of cash, nine months | Cash received | Terms |
|---|---|---|
| Warrants from the January 2025 financing | $203.2M | 35.1M at $5.796 |
| Warrants from the 2023 private placement | $42.7M | 4.3M at $9.93 |
| February underwritten offering | $140.6M | 17.5M shares at $8.00, plus 1.25M pre-funded warrants |
| At-the-market sales | $25.6M | 1.9M shares, average $13.77 |
| Hercules loan refinancing | $18.6M | Debt |
| Options and employee purchase plan | $2.4M | Equity |
Warrant rows are exercise proceeds; the offering, at-the-market and loan rows are net of costs. A pre-funded warrant is paid for up front and costs $0.0001 per share to exercise. Source: Compass Form 10-Q for the quarter ended September 30, 2026.
The largest source was not a 2026 decision. The January 2025 warrants became exercisable after a data milestone, and holders exercised all of them in February 2026, after the second Phase 3 trial reported. Holders of 15.2 million took shares. Holders of the other 19.9 million took pre-funded warrants and paid the full $5.796 up front. Together with the 2023 warrants, the older instruments supplied $245.9 million. The February offering, at-the-market sales (a broker selling new shares at prevailing prices) and the loan refinancing supplied $184.8 million of new money.
Why the $296.7 million warrant liability is prepaid stock, not debt
The largest liability on Compass’s balance sheet is $296.7 million of warrant liabilities, classified as current. All of it relates to the 23,848,829 pre-funded warrants outstanding at September 30. Holders have already paid for them, and each can be exercised for one share at $0.0001, or with no cash payment at all. The filing says Compass “will not receive any meaningful amount of additional funds” when they are.
They count as a liability because, the filing says, they carry contingent exercise provisions that do not meet the indexation guidance in accounting rule ASC 815-40 and could require the company to pay cash to settle them. The 10-Q applies that reasoning to all of the pre-funded warrants but does not say which provisions it means. The pre-funded warrant forms the company filed, from January 2025 and February 2026, contain one clause that has the company buy back a warrant for cash: in a fundamental transaction such as a merger or tender offer, the part of a warrant that a holder’s ownership cap (9.99% unless the holder changed it) would block from exercising just before closing is bought out at Black-Scholes value, paid by the company or its successor. The filings do not identify the form that governs the 19.9 million pre-funded warrants issued when the 2025 warrants were exercised, so the buyout is confirmed only for the forms filed. The filing does not say how much of the $296.7 million that could involve, and it shows no cash payment due now, although it lists the liability as current. They are restated at fair value every quarter, which for a $0.0001 warrant tracks the share price: $296.7 million over 23.8 million warrants is about $12.44 each (Behavioral Wire’s division). Exercising them in the ordinary way would add shares equal to about 17% of the 141.7 million now outstanding, for no meaningful cash. For shareholders that is dilution, not a cash outflow and not new money.
That also explains the quarter. With none exercised, the warrants’ fair value fell $40.8 million, from about $14.15 to about $12.44 each, and the decline is recorded as a gain. The bridge from a $56.4 million operating loss to a $9.8 million net loss is that gain, $4.7 million of net other income (mostly interest and R&D tax credits) and a $1.1 million income-tax benefit. The same rule has cut the other way: the warrant line was a $101.3 million loss in the third quarter of 2025 and a $33.9 million loss across the first nine months of 2026. Reported earnings will keep moving with the share price while the pre-funded warrants are outstanding, a point the company’s results release makes itself.
Basic shares rose 47.5%. Counting warrants, the base rose about 14%
Ordinary shares outstanding rose from 96.1 million to 141.7 million. (Compass stock trades as American depositary shares, each representing one ordinary share; this article calls both shares.) That overstates the new stock issued in 2026, because 25.5 million of the 45.6 million shares added came from exercising instruments sold in 2023 and January 2025, and the count leaves out prepaid shares still held as warrants. The filing says exercising every outstanding warrant would add 31,968,390 shares, a total that includes the 23.8 million pre-funded warrants, the 8.0 million 2023 warrants and a small lender warrant. Counting shares and warrants together, and excluding 10.4 million employee options and 1.9 million unvested stock units, the base rose from about 152 million at the start of the year to about 174 million, roughly 14%. That is a Behavioral Wire calculation from the filings’ warrant disclosures, and the increase of about 21 million is mostly the February offering’s 18.75 million shares and pre-funded warrants.
Selling and administrative costs overtook research
The line Compass now calls selling, general and administrative expense was $33.0 million in the third quarter, up from $13.2 million a year earlier and $23.2 million in the second quarter. Research and development fell to $23.5 million as Phase 3 trial costs wound down. Compass called this line general and administrative until this quarter; prior-year figures match, so the series is comparable.
The filing attributes the $19.8 million rise over the year-earlier quarter primarily to commercial readiness: commercial infrastructure, market access and reimbursement, supply-chain readiness and other launch preparation. Personnel costs rose to $12.9 million from $4.8 million, and the filing ties the increase in personnel and share-based compensation to “increasing staffing levels to support our commercial preparedness activities.”
Not all of the $33.0 million is launch spending. The line also covers public-company costs and support for research, and the filing does not separate them from launch preparation. The release says a commercial team is in place and sales-team selection is underway, and the 10-Q says Compass expects pre-commercialization spending to increase. All of it comes before approval: the release says the final part of the rolling new drug application “will be filed in the next two weeks,” and the 10-Q says approval and state and federal rescheduling of psilocybin must come before commercialization.
What “into 2028” covers, and what remains available
The release describes the $444 million as “providing cash well beyond launch and into 2028.” The 10-Q is narrower. It says existing cash will fund operating expenses and capital expenditure “into 2028,” that the estimate rests on “assumptions that may prove to be wrong,” and that the company is “unable to estimate the exact amount” of its working-capital needs. The only financing it says was left out of the estimate is the remaining 2023 warrants; it does not say how the estimate treats at-the-market sales or further loan draws. Compass also carries $51.0 million of debt, with no principal due before 2029.
The filings show what the estimate has to cover, not whether it holds. Cash used in operations, as Behavioral Wire derives it from the year-to-date statements, was $47.9 million, $40.3 million and $50.8 million in the first three quarters, while selling, general and administrative expense rose from $16.4 million to $33.0 million. For illustration only, not as a forecast, an exhaustion date or a check on the company’s estimate: at the third-quarter rate $444.0 million would last about 8.7 quarters, and at a hypothetical $75 million a quarter about six. The first- and second-quarter 10-Qs gave the same “into 2028” on $466.0 million and $433.3 million. The same loan requires Compass to hold cash of at least 55% of the debt balance, about $27.5 million on the $50.0 million term loan, from October 1, 2027. That is a balance to be kept, not an expense, but while it applies that cash cannot be spent. The requirement has milestone-linked adjustments and an exemption at a market capitalization of at least $850 million (Note 5 adds that milestones must be met), and the filing does not say whether “into 2028” counts that balance as available.
If the launch comes on the company’s first-half 2027 schedule, the stated runway would extend some months past it. That is a statement about funding a launch and its first months, not about reaching meaningful revenue or breakeven, and the filing says it is uncertain “when, if ever” the company will realize revenue from sales.
Four other sources could add money, and each is a different kind of thing:
- Conditional: the Hercules loan. Up to $30 million more if certain FDA approvals are granted and $20 million on a commercial milestone, plus further amounts subject to the lender’s investment committee.
- Depends on holders and the share price: the 2023 warrants. 8,025,339 remain at $9.93, worth up to $79.7 million if all are exercised for cash. The exercise period ends in February 2027, and the runway estimate excludes this money.
- Authorized but unused: the at-the-market program. About $123.8 million of capacity remains.
- A registration, not cash: the automatic shelf. Filed in August, it lets Compass sell an indeterminate amount of shares, debt, warrants and units without a new SEC review. It raises nothing by itself.
These are not a total, and none is cash in hand.
What the financing leaves open
Compass reached the end of its Phase 3 program with $444.0 million, a loan with no principal due before 2029, and an estimate that its cash extends past its expected launch. The cost of that financing is paid in shares, and the remaining sources are mostly equity that depends on the share price.
Between here and launch sit steps that cash does not settle: the FDA decision on an application Compass says it will complete within two weeks, and federal and state rescheduling. The next filings will show whether selling and administrative costs keep rising and how much of the 2023 warrants and at-the-market capacity gets used. Until then, the $444.0 million is the one figure in hand, and the cost of the launch is not in the filing.